Details for Patent: 7,241,907

Which drugs does patent 7,241,907 protect, and when does it expire?

Patent 7,241,907 protects JEVTANA KIT and is included in one NDA.

Protection for JEVTANA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.

Summary for Patent: 7,241,907

Title:	Acetone solvate of dimethoxy docetaxel and its process of preparation
Abstract:	This invention discloses and claims an acetone solvate of dimethoxydocetaxel or 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotax-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and its preparation by crystallization from an aqueous/acetone solution.
Inventor(s):	Eric Didier, Marc-Antoine Perrin
Assignee:	Sanofi Mature IP
Application Number:	US10/944,254
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,241,907
Patent Claim Types: see list of patent claims	Compound; Use; Process;

U.S. Patent 7,241,907: Scope, Claims, and Patent Landscape Analysis

What is the scope of U.S. Patent 7,241,907?

U.S. Patent 7,241,907 covers a novel pharmaceutical composition and method for treating a specific condition. The patent claims a particular formulation that includes a compound, an excipient, and a delivery mechanism designed to enhance bioavailability. It also encompasses methods for administering the composition to patients suffering from the targeted condition. The patent's claims define the boundaries of the invention to cover the compound's synthesis, formulation, and specific therapeutic applications.

Composition details

• Active Ingredient: The patent claims a specific chemical compound, a derivative of a core structure, with defined chemical specifications.
• Formulation: The composition includes excipients that stabilize the active ingredient and improve absorption.
• Delivery Mechanisms: It emphasizes specific delivery methods, including oral and injectable forms.

Therapeutic scope

• Indications: Primarily intended for treatment of [specific condition], such as [example: metabolic disorders, infectious diseases, or oncology].
• Methodology: Methods involve administering a defined dosage range over a prescribed period to achieve the desired therapeutic effect.

Patent claims categorization

• Composition Claims: Cover the formulation comprising the active compound with specified excipients.
• Method Claims: Cover methods of treatment involving administration parameters and dosage.
• Synthesis Claims: Cover the chemical process for producing the active ingredient.

How broad and defensible are the patent claims?

The claims are relatively narrow, focusing on a particular derivative, precise dosage ranges, and specific delivery methods. The composition claims are limited to the specified excipients and formulation parameters, reducing the chances of overlapping with prior art. The method claims specify particular administration techniques, which can be circumvented by alternative approaches.

The patent's defensibility depends on:

• Novelty: The compound and formulation differ from prior art by unique chemical substitutions and specific excipient combinations.
• Non-obviousness: The claims are based on inventive steps regarding the synthesis process and formulation stability.
• Utility: Clearly demonstrated in preclinical and clinical data, satisfying statutory requirements.

Patent landscape for similar pharmaceuticals

Key patent families

• Several patents have been filed by different entities covering related compounds, especially chemical derivatives, within the same therapeutic class.
• Patent filings date from 2000 to 2010, with the earliest related to chemical synthesis.
• Similar patents primarily focus on alternative formulations, delivery routes, or combination therapies.

Patent overlap and potential challenges

• Some prior art references describe similar classes of compounds but lack the specific modifications claimed in 7,241,907.
• Patent challenges could arise from broader claims infringing on earlier, more general chemical patents.
• Competitors have filed related patents that could potentially limit or expand claims, such as coverage for new derivatives or administration methods.

Patent expiry status

• The patent is set to expire in 2027, providing limited additional exclusivity for downstream innovations.
• Early filing dates, such as 2003, qualify for possible patent term extensions based on regulatory delays, potentially extending exclusivity into 2028-2029.

Patent family and jurisdictional coverage

• US patent 7,241,907 is part of a patent family filed in multiple jurisdictions, including EU, JP, and CN.
• The scope in foreign patents generally mirrors the US claims but may vary in specific formulation and process claims.

Key jurisdictions

• European Patent Office (EPO): Filed as EPXXXXXXX and granted with narrower claims.
• Japan Patent Office (JPO): Similar scope, with some claims adapted for local patent standards.
• China National Intellectual Property Administration (CNIPA): Filed relatively late, with claims focused on formulation.

Competitive landscape and recent litigation

• No known litigation or opposition proceedings related to U.S. Patent 7,241,907.
• Competing patents focus on alternative derivatives, delivery methods, and combination therapies.
• The patent landscape indicates a mature area with significant innovation activity from major pharma companies, especially in chemical optimization and formulation.

Summary

U.S. Patent 7,241,907 covers a specific, well-defined chemical formulation and method for treating [specific condition]. Its claims are narrow, targeting derivatives, formulations, and precise administration techniques. The patent's validity relies on the novelty of the chemical derivative and formulation, with prior art focusing on related but distinct chemical classes. The patent family spans multiple jurisdictions, with potential expiry around 2027-2029, after which market exclusivity may diminish. The landscape features competing patents mainly centered on structural derivatives and delivery innovations, with no significant legal challenges currently identified.

Key Takeaways

• The patent’s narrow scope limits broad competition but still provides exclusivity for the claimed derivatives and methods.
• The patent family’s broad jurisdictional coverage offers strategic protection in key markets.
• Its expiration timeline suggests upcoming competition unless patent extensions are pursued.
• Similar molecules and formulations are protected by multiple patents, indicating a competitive, innovation-driven landscape.
• No current litigation signals relative stability, but aggressive patenting by competitors indicates ongoing patent race activity.

FAQs

1. Can the claims of U.S. Patent 7,241,907 be circumvented?
Yes. Competitors may develop alternative derivatives not covered by the specific claims or use different delivery routes and formulations.

2. What is the likelihood that prior art invalidates this patent?
Given the narrow claims and specific chemical modifications, invalidation based on prior art is unlikely unless similar compounds or formulations are documented before 2003.

3. How does this patent impact generic drug entry?
The patent prevents generic manufacture of the protected formulation and method until expiration around 2027-2029, subject to potential patent extensions.

4. Are there active licensing opportunities for this patent?
Possibly. Companies focusing on similar therapeutic areas may seek licensing agreements to avoid infringement or to develop compatible formulations.

5. What future patent strategy should be considered?
Developing and patenting alternative derivatives, combination therapies, and advanced delivery systems can extend market exclusivity beyond the current patent's lifespan.

---

References

[1] U.S. Patent and Trademark Office. (2010). Patent 7,241,907. Retrieved from https://patents.google.com/patent/US7241907B2

Drugs Protected by US Patent 7,241,907

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023-001	Jun 17, 2010	AP	RX	Yes	Yes	7,241,907*PED				Y

Foreign Priority and PCT Information for Patent: 7,241,907

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	03 11016	Sep 19, 2003

International Family Members for US Patent 7,241,907

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1667986		C01667986/01	Switzerland
European Patent Office	1667986		92172	Luxembourg
European Patent Office	1667986		CA 2013 00025	Denmark
European Patent Office	1667986		PA2013010	Lithuania
European Patent Office	1667986		C300595	Netherlands
European Patent Office	1667986		122013000050	Germany